title: MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
abstract: Resistance to chemotherapy is a major obstacle for the effective treatment of advanced ovarian cancer. The mechanism of chemoresistance is still poorly understood. Recently, more and more evidence showed microRNAs (miRNAs) modulated many key molecules and pathways involved in chemotherapy. microRNA-106a (miR-106a) has been implicated in many cancers, but its role in ovarian cancer and drug resistance still remains unexplored. This study was to investigate whether miR-106a mediated resistance of the ovarian cancer cell line A2780 to the chemotherapeutic agent cisplatin (DDP). The different levels of miR-106a in A2780 cells and their resistant variant A2780/DDP cells were identified by using real-time PCR. MTT assay and flow cytometry were used to analyze the effect of miR-106a on cisplatin resistance of these paired cells. Real-time PCR, Western blotting and luciferase reporter assay were applied to explore whether Mcl-1 was a target of miR-106a. As compared to A2780 cells, the expression of miR-106a was down-regulated in the cisplatin resistant cell line A2780/DDP. Moreover, knockdown of miR-106a dramatically decreased antiproliferative effects and apoptosis induced by cisplatin in A2780 cells, while overexpression of miR-106a significantly increased antiproliferative effects and apoptosis induced by cisplatin in A2780/DDP cells. Furthermore, miR-106a inhibited cell survival and cisplatin resistance through downregulating the expression of Mcl-1. Mcl-1 was a direct target of miR-106a. These results suggest that miR-106a may provide a novel mechanism for understanding cisplatin resistance in ovarian cancer by modulating Mcl-1.
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. raoyumei01@sina.com.
authors.forename: Yu-Mei
authors.initials: YM
authors.lastname: Rao
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
authors.forename: Hui-Rong
authors.initials: HR
authors.lastname: Shi
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Ji
authors.affiliation: Center of Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
authors.forename: Cai-Hong
authors.initials: CH
authors.lastname: Chen
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C579095:MCL1 protein, human; C542541:MIRN106 microRNA, human; D035683:MicroRNAs; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D002945:Cisplatin
references.citation: N Engl J Med. 1995 Mar 9;332(10):629-34
references.pmid: 7845426
references.citation: Neuro Oncol. 2013 Jun;15(6):707-17
references.pmid: 23416698
references.citation: PLoS One. 2013 Apr 26;8(4):e63032
references.pmid: 23638178
references.citation: Cancer Treat Rev. 2013 Apr;39(2):153-60
references.pmid: 22595680
references.citation: Exp Mol Pathol. 2013 Feb;94(1):148-54
references.pmid: 23178825
references.citation: Mol Carcinog. 2013 Aug;52(8):634-46
references.pmid: 22431000
references.citation: Biochem Pharmacol. 2001 Dec 1;62(11):1469-80
references.pmid: 11728383
references.citation: Cancer Res. 2008 Dec 15;68(24):10307-14
references.pmid: 19074899
references.citation: PLoS One. 2012;7(9):e44413
references.pmid: 22970213
references.citation: Apoptosis. 2013 Apr;18(4):492-508
references.pmid: 23344663
references.citation: Gynecol Oncol. 2009 Aug;114(2):253-9
references.pmid: 19446316
references.citation: J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63
references.pmid: 17105988
references.citation: Clin Transl Oncol. 2011 Jun;13(6):357-62
references.pmid: 21680295
references.citation: Ann Oncol. 2005 May;16 Suppl 4:iv95-101
references.pmid: 15923439
references.citation: Mol Med. 2011;17(11-12):1262-74
references.pmid: 21863213
references.citation: BMC Cancer. 2012 Nov 02;12:505
references.pmid: 23121918
references.citation: Cell. 2003 Jun 13;113(6):673-6
references.pmid: 12809598
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):543
references.pmid: 21823019
references.citation: Mol Cancer Ther. 2009 Nov;8(11):3162-70
references.pmid: 19887550
references.citation: Jpn J Cancer Res. 2002 May;93(5):542-50
references.pmid: 12036450
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):375-382
references.pmid: 22684561
references.citation: Clin Cancer Res. 2006 May 1;12(9):2774-9
references.pmid: 16675570
references.citation: FEBS J. 2012 Jun;279(11):2047-59
references.pmid: 22498306
references.citation: J Clin Invest. 2010 Oct;120(10):3594-605
references.pmid: 20811155
references.citation: Oncol Rep. 2012 Aug;28(2):592-600
references.pmid: 22614869
references.citation: Mol Cancer Ther. 2009 May;8(5):1055-66
references.pmid: 19435871